These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17343261)

  • 1. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate.
    Knudsen LS; Ostergaard M; Baslund B; Narvestad E; Petersen J; Nielsen HJ; Ejbjerg BJ; Szkudlarek M; Johansen JS
    Scand J Rheumatol; 2006; 35(6):489-91. PubMed ID: 17343261
    [No Abstract]   [Full Text] [Related]  

  • 2. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
    Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
    Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
    Knudsen LS; Klarlund M; Skjødt H; Jensen T; Ostergaard M; Jensen KE; Hansen MS; Hetland ML; Nielsen HJ; Johansen JS
    J Rheumatol; 2008 Jul; 35(7):1277-87. PubMed ID: 18597410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity.
    Johansen JS; Stoltenberg M; Hansen M; Florescu A; Hørslev-Petersen K; Lorenzen I; Price PA
    Rheumatology (Oxford); 1999 Jul; 38(7):618-26. PubMed ID: 10461474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In early rheumatoid arthritis the combination of methotrexate and infliximab over 2 years reduces the progression of radiological lesions more than methotrexate alone.
    Montecucco C
    Clin Exp Rheumatol; 2005; 23(3):289-291. PubMed ID: 15971414
    [No Abstract]   [Full Text] [Related]  

  • 6. A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure.
    Hambardzumyan K; Saevarsdottir S; Forslind K; Petersson IF; Wallman JK; Ernestam S; Bolce RJ; van Vollenhoven RF
    Arthritis Rheumatol; 2017 May; 69(5):953-963. PubMed ID: 27992691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of ultrasound subclinical synovitis and increment of serum vascular endothelial growth factor in a patient with rheumatoid arthritis achieved in sustained clinical remission by treatment with adalimumab and methotrexate.
    Kawashiri SY; Arima K; Suzuki T; Nakashima Y; Horai Y; Okada A; Tamai M; Nakamura H; Kawakami A
    Mod Rheumatol; 2014 Jul; 24(4):681-4. PubMed ID: 24533548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
    N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors.
    Pedersen SJ; Hetland ML; Sørensen IJ; Ostergaard M; Nielsen HJ; Johansen JS
    Clin Rheumatol; 2010 Nov; 29(11):1301-9. PubMed ID: 20640910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of golimumab combined with methotrexate on radiographic progression in rheumatoid arthritis: comment on the article by Emery et al.
    Graudal N; Jürgens G
    Arthritis Rheum; 2012 Apr; 64(4):1297-8; author reply 1298-9. PubMed ID: 22231914
    [No Abstract]   [Full Text] [Related]  

  • 12. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J; Kishimoto T
    Mod Rheumatol; 2009; 19(1):12-9. PubMed ID: 18979150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA.
    Erlandsson MC; Forslind K; Andersson SE; Lund A; Bokarewa MI
    Rheumatology (Oxford); 2012 May; 51(5):932-40. PubMed ID: 22258387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cystatin C level in patients with rheumatoid arthritis after single infusion of infliximab.
    Kopec-Medrek M; Widuchowska M; Kotulska A; Zycinska-Dębska E; Kucharz EJ
    Rheumatol Int; 2011 Sep; 31(9):1255-6. PubMed ID: 20658289
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis.
    Cobo Ibáñez T; Yehia Tayel M; Balsa Criado A; Hernández Sanz A; Martín Mola E
    Rheumatology (Oxford); 2005 Nov; 44(11):1467-8. PubMed ID: 16174647
    [No Abstract]   [Full Text] [Related]  

  • 16. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-a blockade in patients with rheumatoid arthritis.
    Macías I; García-Pérez S; Ruiz-Tudela M; Medina F; Chozas N; Girón-González JA
    J Rheumatol; 2005 Nov; 32(11):2102-8. PubMed ID: 16265686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between serum levels of YKL-40 and disease progression in patients with early rheumatoid arthritis.
    Harvey S; Whaley J; Eberhardt K
    Scand J Rheumatol; 2000; 29(6):391-3. PubMed ID: 11132209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters.
    Matsumoto T; Tsurumoto T
    Clin Exp Rheumatol; 2001; 19(6):655-60. PubMed ID: 11791636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study.
    Strunk J; Bundke E; Lange U
    Rheumatol Int; 2006 Jan; 26(3):252-6. PubMed ID: 15999273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents.
    Ikeda K; Nakagomi D; Sanayama Y; Yamagata M; Okubo A; Iwamoto T; Kawashima H; Takahashi K; Nakajima H
    J Rheumatol; 2013 Dec; 40(12):1967-76. PubMed ID: 24187096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.